Friday, 16 October 2026European Markets

Selloff Continues: PIERRE VAC Shares Down 31% In Last 10 Sessions

Loading stream...

(vianews) - investors of pierre vac bsa cre (vacbt.pa) are taking a beating as its shares dipped 31.82% over 10 sessions, from eur0.44 to eur0.30 at 15:27 est on friday - this marks five consecutive sessions of losses for this cac 40 company listed under vacbt.pa's ticker symbol vacbt.pa; while overall cac 40 index rose by 0.22% to eur7,326.80 vacbt.pa still struggled; its closing price of eur0.30 represents a 16.67% drop from its 52 week high of eur0.36

yearly analysis

pierre vac bsa cre is currently trading below its 52-week low of eur0.30 and this suggests that its stock has been underperforming over the past year. while this trend may continue for now, investors must carefully evaluate other factors like company financials, industry outlook and overall market conditions before making investment decisions. it is highly advised to conduct an analysis as well as seek professional guidance before investing.

more news about pierre vac bsa cre (vacbt.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com